The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List


Wed, Mar 26, 4:10 PM, Zacks
ARIAD Candidate in Phase II Study - Analyst Blog
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).

Wed, Mar 5, 9:58 AM, Zacks
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.

ARIAD Pharmaceuticals, Inc. (ARIA)

ARIAD Pharmaceuticals is engaged in the development and commercialization of small-molecule drugs to treat cancer patients. Co.'s commercial product is Iclusig™ (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to other TKI therapies. Co. also has two other product candidates in development: AP26113, which is being studied in patients with advanced solid tumors including non-small cell lung cancer; and ridaforolimus, which is being studied in patients with various types of cancers.

Company Name:  ARIAD Pharmaceuticals, Inc.
Sector:  Biotechnology
Number of ETFs Holding ARIA:  26
Total Market Value Held by ETFs:  $53.95M
Total Market Capitalization:  $1.33B
% of Market Cap. Held by ETFs:  4.06%
April 16, 2014    3:13 AM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade ARIA Now:

Hold (2.50 out of 4)
25th percentile
(ranked lower than approx. 75% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

ARIAD Pharmaceuticals, Inc. (ARIA) Page | The Online Investor | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.